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Objective: To test whether the newly developed comprehensive complication
index (CCI) is more sensitive than traditional endpoints for detecting between-
group differences in randomized controlled trials (RCTs).
Background: A major challenge in RCTs is the choice of optimal endpoints
to detect treatment effects. Mortality is no longer a sufficient marker in studies,
and morbidity is often poorly defined. The CCI, integrating all complications
including their severity in a linear scale ranging from 0 (no complication) to
100 (death), is a new tool, which may be more sensitive than other traditional
endpoints to detect treatment effects on postoperative morbidity.
Methods: The CCI was tested in 3 published RCTs from European centers
evaluating pancreas, esophageal and colon resections. To compare the sensi-
tivity of the CCI with traditional morbidity endpoints, for example, presence
of any (yes/no) or only the most severe complications, all postoperative events
were assessed, and the CCI calculated. Treatment effects and sample size
calculations were compared using the CCI and traditional endpoints.
Results: Although RCTs failed to show between-group differences using any
or most severe complications, the CCI revealed significant differences between
treatment groups in 2 RCTs—after pancreas (P = 0.009) and esophageal
surgery (P = 0.014). The CCI in the RCT on colon resections confirmed the
absence of between-group differences (P = 0.39). The required sample sizes
in trials are up to 9 times lower for the CCI than for traditional morbidity
endpoints.
Conclusions: This study demonstrates superiority of the CCI to traditional
endpoints. The CCI may serve as an appealing endpoint for future RCTs and
may reduce the sample size.
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A major challenge in designing randomized controlled trials(RCTs) is the choice for objective, concise, and clinically rele-
vant endpoints. Mortality is no longer an acceptable primary endpoint
in surgical studies given the sharp decline in mortality for most pro-
cedures in the past decades. Morbidity is often poorly defined, which
has led to inconsistent reporting and confusion in the literature.1–7
Furthermore, most authors have reported only the most severe compli-
cations or only events judged to be relevant but ignored complications
of lesser magnitude as well as the total number of complications.5 To
address this issue, the Comprehensive Complication Index (CCI) was
recently introduced. It integrates all postoperative complications with
their respective severities, on a scale ranging from 0 (no burden from
complications) to 100 (death).8
The CCI, summarizing the entire postoperative experience of
the patient with respect to complications, is based on the widely es-
tablished Clavien-Dindo classification.3,8 Validations from 4 different
perspectives showed that the CCI is a valid endpoint for postopera-
tive overall morbidity. Although the CCI is an attractive novel tool,
which may serve as a primary or secondary endpoint in many types
of studies, the external validity has not been tested in RCTs. There-
fore, the aim of this study was to externally evaluate whether the
CCI is more sensitive than traditional primary endpoints in detecting
between-group differences.
METHODS
We externally validated the CCI8 on recently published
RCTs9-11 that reported specific complications after different surgi-
cal procedures. The first step was to identify and contact a number
of centers, which have conducted RCTs investigating specific and
nonspecific morbidity endpoints. We considered RCTs regardless of
their conclusions in the original analysis and focused on different
types and complexity of general surgical procedures, different dis-
eases, and countries. All RCTs with a proper study design according
to the CONSORT guidelines were identified by a systematic literature
search in peer-reviewed high impact journals in the last 3 years (2011-
2013)12-15 (Supplemental Digital Content 1: flow diagram, available
at http://links.lww.com/SLA/A658). After contacting several centers
in general, cardiac, and plastic surgery, we were granted full access
to primary data and each patient record of 3 European trials9-11 ad-
dressing different surgical interventions and diseases in compliance
with our study design. The first trial focused on the rate of pancre-
atic fistulas after pancreaticoduodenectomy.11 The second trial was
evaluating the rate of anastomotic strictures after 2 different types
of anastomosis after esophagectomy9 and, finally, the third trial fo-
cused on the rate of overall complications after colon resection for
perforated diverticulitis.10
Primary data9–11 were reanalyzed including calculation of the
CCI in each patient. The CCI of the comparative groups in each
trial was tested along traditional reported morbidity endpoints in
the literature including the presence of any complication (yes/no)
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and the most severe complications (≥grade IIIb according to the
Clavien-Dindo classification3). The first author (K.S.) visited each
center to secure consistent and exhaustive reevaluation of the data.
The multicenter RCT originating from France, published
in 2011, was designed to test whether an external pancreatic
duct stent might reduce the rate of pancreatic fistulas after
pancreaticoduodenectomy.11 A sample size calculation postulated a
10% reduction in the incidence of pancreatic fistulas in patients with
pancreatic stents compared to those without drainage11. Assuming
a power of 80% and an α-error of 0.05, the investigators enrolled
158 patients comparing 77 patients with, versus 81 without insertion
of an external stent drainage (Fig. 1).11 The results indicated that
external stent drainage of the pancreatic duct significantly reduces
the risk of pancreatic fistulas, as well as overall morbidity rates after
pancreaticoduodenectomy.11
The second RCT, performed in the Netherlands from 2005 to
2007, compared an end-to-end (E-E) with end-to-side (E-S) esoph-
agogastrostomy after esophageal cancer resection (Fig. 1).9 Their
primary endpoint was the development of anastomotic stricture and
need for dilatation within 1 year after surgery. They, therefore, per-
formed a noninferiority trial with one-sided testing assuming a 50%
reduction in the rate of stenosis in patients with E-S comparing to
E-E anastomosis. Assuming a power of 80% and an α-error of 0.05,
64 patients per group were required. The authors observed a lower
incidence of anastomotic stricture in patients with E-S anastomo-
sis. They also concluded that E-S anastomosis was associated with
significantly more anastomotic leaks than E-E anastomosis.9 The au-
thors, however, did not investigate the overall morbidity expressed as
the presence of any complication, nor the most severe complication
(≥grade IIIb).
Finally, the third multicenter RCT focused on patients with
perforated left-sided diverticulitis enrolled from 4 surgical centers in
Switzerland (including the Department of Surgery at the University
Hospital Zurich).10 The study was designed to test whether the con-
ventional Hartmann’s procedure (HP: colonic resection with closure
of the rectal stump and an end-colostomy) is comparable to a pri-
mary anastomosis (PA) with diverting ileostomy (Fig. 1) using the
rate of overall complications, regardless of the severity, as the main
endpoint. Both strategies require a second operation, that is, stoma
reversal and in HP a reestablishment of the continuity of the colon.
For the sample size calculation, 25% reduction in the rate of overall
complications was assumed with a power of 80% and an α-error of
0.05. This yielded an estimated group size of 68 patients. The planned
interim analysis, enrolling 62 patients, lead to a discontinuation of the
trial, as recommended by the data-monitoring board, due to signifi-
cant differences in adequately powered relevant secondary endpoints.
Thirty patients had been randomized for the HP procedure and 32
for a primary anastomosis. Although the overall complication rates
for both resection and stoma reversal operations were comparable,
severe complications (grades ≥IIIb) were significantly reduced after
reversal operations in the PA group.10
Data Collection and Primary Endpoint
We used the existing databases of these 3 RCTs and calculated
the CCI for each patient.9–11 Each postoperative event in each pa-
tient was assessed on site and graded according to the Clavien-Dindo
classification, which is based on the treatment used to correct the post-
operative complication.3 For the development of the CCI, we used the
established Clavien-Dindo classification system3 for complications,
adopting methods from operation-risk-index analysis in marketing
research and developed a formula that considers any combination
of complications.16–18 The CCI was finally calculated as the sum of
all complications that are weighted for their severity by patients and
physicians.8,19 The final formula yields a score from 0 (no complica-
tion) to 100 (death).8 The CCI can easily be calculated online by free
access at www.assessurgery.com.
In addition, for each patient, we assessed traditional morbidity
endpoints: the total number of complications, the presence of any
(yes/no), and the most severe (≥grade IIIb3) complications. In the
esophageal stricture trial, we also calculated the CCI at discharge
and a long-term CCI after 1 year after initial surgery in all patients.
The longitudinal assessment of the overall morbidity using the CCI is
novel allowing to present the cumulative effects of complication over
time.
FIGURE 1. The 3 European randomized controlled trials.9–11
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In-hospital costs, the length of hospital stay (LOS) and in-
tensive care unit (ICU) stay were also extracted from the respective
original database. LOS and ICU stay were available in all 3 RCTs,
whereas the in-hospital costs were only available in the multicenter
colon RCT.
We additionally performed a sample size calculation to prop-
erly evaluate the sensitivity of the CCI as primary endpoint in trials.
We assumed a difference of 10 points for the CCI, a relative risk re-
duction of 40% for the specific and traditional morbidity endpoints, a
power of 80%, and an α-error of 0.05. The difference of 10 points on
the CCI scale is chosen because it reflects 1-grade difference in the
established Clavien-Dindo classification. For the colon trial, we were
not able to calculate a sample size because of premature termination
of the initial trial, a 2-step procedure and therefore unequal group
sizes (n = 15 vs n = 22) in the second surgery.
Eligibility criteria (Supplementary Digital Content 2, avail-
able at http://links.lww.com/SLA/A658) and the paragraph about the
statistical analysis (Supplementary Digital Content 3, available at
http://links.lww.com/SLA/A658) are reported in detail in the supple-
mental materials.20–22 For all results, we reported point estimates,
95% confidence intervals (CIs), and P values (≤0.05 considered sig-
nificant). We performed statistical analyses using STATA (version 11,
Stata Corp, College Station, Texas).
RESULTS
As summarized in Figure 1, we reanalyzed 348 patients for
which detailed characteristics were reported previously.9–11
Conventional Morbidity Endpoints Versus CCI
In the pancreatic fistula trial, the overall burden of the post-
operative morbidity represented by the median CCI after pancreati-
coduodenectomy was significantly lower in patients with an external
pancreatic stent than in those without any drainage [0 (IQR [interquar-
tile range]: 0–26.2) vs 20.9 (IQR: 0–29.6), P = 0.009] (Table 1).
In contrast, there was no between-group difference considering the
“most severe complication” in patients with the external stent com-
pared with those ones without stent (13% vs 11%, 95% CI: 0.5–3.1,
P = 0.72). The authors of this trial published a significant between-
group difference in the rate of pancreatic fistulas (42% without stent
vs 26% with stent, P = 0.035).11 These findings support the higher
sensitivity of the CCI because the between-group difference for the
CCI presented lower P values (P = 0.009) as indirect comparison of
effect sizes, than the differences for the specific complication “pancre-
atic fistula” (P= 0.035), as well as for the “most severe complication”
(P = 0.72) in the same patient population.20,21 The P values for the
CCI (P= 0.009) compared to those ones for the presence of any com-
plications (P = 0.008) were similar in the same patient population
(Table 1).
In the esophageal anastomosis trial, patients with an E-S anas-
tomosis disclosed significantly higher CCI at discharge than patients
with an E-E anastomosis [22.6 (IQR: 0–41.2) vs 10.5 (IQR: 0–24.4),
P = 0.014]. In contrast, this trial failed to show any statistically sig-
nificant between-group differences using traditional endpoints such
as the presence of any or the most severe complications (≥grade IIIb)
(Table 2).
TABLE 1. Effects of Stent Versus No Stent on Postsurgical Morbidity Using Different Measurements in Patients With Pancreatic
Fistula Following Pancreaticoduodenectomy11
Without With Unadjusted
Stent (n = 81) Stent (n = 77) Difference (95% CI, P)
CCI 20.9 (0–29.6) 0 (0–26.2) − 12.2 (−4.5 to −16.7, P = 0.009)
CCI of the pancreatic fistula 0 (0–20.9) 0 (0–8.7) − 3.2 (−6.8 to 0.5, P = 0.091)
Number of complications 1 (0–2) 0 (0–1) − 0.5 (−0.9 to −0.1, P = 0.021)
Without With Unadjusted
Stent (n = 81) Stent (n = 77) Odds Ratio (95% CI, P)
Presence of any complication (%) 50 (61.7%) 32 (41.5%) 0.4 (0.2–0.8, P = 0.008)
Severe complications ≥ IIIb∗ (%) 9 (11.1%) 10 (13.0%) 1.2 (0.5–3.1, P = 0.72)
Pancreatic fistula (%) 34 (42%) 20 (26%) 0.5 (0.2–0.95, P = 0.035)
CI = confidence interval, CCI = Comprehensive Complication Index; all results reported as median and interquartile range; ∗grading of complications according to the
Clavien-Dindo classification system3.
TABLE 2. Effects of End-to-End Versus End-to-Side Anastomosis on Postsurgical Morbidity Using Different Measurements in
Patients With Anastomotic Stricture After Esophagectomy9
Unadjusted
E-E (n = 64) E-S (n = 64) Difference (95% CI, P)
CCI at discharge 10.5 (0–24.4) 22.6 (0–41.2) 11.6 (2.4–20.8, P = 0.014)
CCI after 1 year 26.2 (20.9–40.6) 26.2 (8.7–38.2) − 1.4 (−10.3 to 7.4, P = 0.75)
No. complications 1 (0–2) 1 (0–2.5) 0.5 (−0.1 to 1.1, P = 0.08)
Unadjusted
E-E (n = 64) E-S (n = 64) Odds Ratio (95% CI, P)
Presence of any complication (%) 42 (65.6%) 47 (73.4%) 1.5 (0.7–3.1, P = 0.34)
Severe complications ≥ IIIb∗ (%) 11 (17.2%) 20 (31.3%) 2.2 (0.95–5.1, P = 0.07)
Anastomotic stricture (%) after 1 year 20 (40%) 10 (18%) 0.3 (0.1–0.7, P = 0.004)
Anastomotic leakage (%) 14 (22%) 26 (41%) 3.4 (1.4–8.2, P = 0.04)
All results were presented in median and IQR.
∗Grading of complications according to the Clavien-Dindo classification system.3
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The original analysis of this trial reported a significantly higher
rate of stricture in the anastomosis 1 year after the initial surgery (40%
in E-E vs 18% in E-S, P < 0.01).9 The CCI directly after discharge
was significantly different between both groups, mostly related to a
significantly higher rate of anastomotic leaks in the E-S anastomosis
group [odds ratio: 3.4 (95% CI: 1.4–8.2, P = 0.04]. After calculating
the CCI at 1-year follow-up (including stricture), however, the median
CCI was similar between patients with E-E and E-S anastomosis [26.2
(20.9–40.6) vs 26.2 (8.7–38.2), P = 0.75]. This new finding suggests
that there is no long-term difference (after 1 year) in the morbidity
between both types of anastomoses. The CCI allows reporting of
complications that occur during different time periods. After 1-year
follow-up, the CCI (P = 0.75) balances the initially higher rate of
anastomotic leaks in patients with E-S anastomosis (P = 0.04) with
the increasing rate of anastomotic strictures in patients with E-E
anastomosis (Table 2). Thus, although initially 1 patient group seems
to have an advantage, long-term observations reverse this observation
by considering late complications experienced by the other group of
patients.
In the multicenter colon trial, there was no significant differ-
ence in the overall CCI, neither for the overall procedures nor in the re-
spective steps (first and second operation). Nevertheless, the between-
group difference of the CCI demonstrated a lowerP value than the dif-
ferences in traditional morbidity endpoints that emphasize the higher
sensitivity of the CCI over the traditional endpoints (Table 3).20,21
This trial showed comparable between-group complication rates
for both surgical steps. Comparing the outcome of the first op-
eration between the groups, there was also no significant differ-
ence in the rate of severe complications (44% vs 37%, P = 0.57;
Table 3).
The CCI and the Sample Size
For 2 trials, a sample size calculation was performed for their
specific endpoint, the CCI and traditional morbidity endpoints (any or
most severe complications). The sample sizes are clearly lower for the
CCI compared to the original and traditional endpoints as shown in
Table 4. This illustrates the putative benefits of the CCI compared to
complication endpoints such as any and more severe in minimizing
the need for large sample sizes in the future. For example, in the
pancreatic fistula trial, the required sample size would decrease from
695 patients/group to 76 patients per group when using the primary
endpoint CCI vs. “most severe complication”. Similar results were
seen in the esophageal anastomosis trial (Table 4).
CCI Associated to LOS, ICU Stay, and In-Hospital
Costs
The CCI was significantly associated to LOS and ICU
stay in all 3 trials (Supplementary Digital Content 4, available at
http://links.lww.com/SLA/A658). We also evaluated the costs of
TABLE 3. Effects of the Hartmann’s Procedure Versus Primary Anastomosis on Postsurgical Morbidity Using Different
Measurements in Patients With Perforated Diverticulitis10
Hartmann’s Primary Unadjusted
Procedure Anastomosis Difference
n = 30 n = 32 (95% CI, P)
CCI for both surgeries 40.3 ± 32.6 33.5 ± 28.3 6.8 (−8.7 to 22.3, P = 0.39)
CCI after first surgery 37.3 ± 33.1 32.2 ± 28.4 5.1 (−10.5 to 20.7, P = 0.52)
CCI after second surgery n = 15, 12.4 ± 16.7 n = 22, 5.2 ± 9.7 7.2 (−1.7 to 16.0, P = 0.11)
Hartmann’s Primary Unadjusted Odds Ratio
Procedure Anastomosis (95% CI, P)
First surgery n = 30 n = 32
Any morbidity (%) 24 (80%) 27 (84.4%) 0.74 (0.20–2.74; P = 0.65)
Severe complications ≥ IIIb∗ (%) 11 (36.7%) 14 (43.8%) 0.74 (0.27–2.1, P = 0.57)
Unadjusted Odds Ratio
Second surgery n = 15 n = 22 (95% CI, P)
Any morbidity (%) 6 (40%) 6 (27.3%) 1.78 (0.44–7.18, P = 0.42)
Severe complications ≥ IIIb∗ (%) 3 (20%) 0% —
All results reported as mean ± standard deviation. No statistical analysis was performed if ≤5 events in a group.
∗Grading of complications according to the Clavien-Dindo classification system.3
TABLE 4. Sample Size Calculation for Surgical RCTs Using Different Measurements for Postsurgical Morbidity
Assumptions Sample Size
Pancreatic fistula trial11
Pancreatic fistula11 40% relative risk reduction 149 patients/group
Presence of any complication (yes/no) 40% relative risk reduction 75 patients/group
Most severe complication ≥ IIIb∗ 40% relative risk reduction 695 patients/group
CCI  10 points, SD = 22 76 patients/group
Esophageal anastomosis trial9
Anastomotic stricture9 40% relative risk reduction 132 patients/group
Presence of any complication (yes/no) 40% relative risk reduction 76 patients/group
Most severe complication ≥ IIIb∗ 40% relative risk reduction 220 patients/group
CCI  10 points, SD = 20 63 patients/group
β = 0.8; α = 0.05;  = difference in 10 points in the CCI scale.
∗Grading of complications according to the Clavien-Dindo classification system.3 Sample sizes were shown without considering loss of follow-up.
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complications in the colon trial. An increase in one point on the CCI
scale created additional costs of Swiss Franc (CHF) 883 (95% CI:
222–1543, P = 0.010) (about US$ 980, 95% CI: 247–1714). In other
words, an increase of the CCI of 10 points on the scale increases
the in-hospital costs to additional US$ 9800 (Supplementary Digital
Content 4, available at http://links.lww.com/SLA/A658).
DISCUSSION
This study demonstrates the superiority of the CCI over tra-
ditionally reported morbidity endpoints “most severe complication”
and specific complications by detecting between-group differences
in 3 external trial populations. Another finding is the easy and new
applicability to longitudinal assessment of complications over time,
as illustrated in the analysis of the 1-year CCI follow-up in the
esophageal anastomosis trial. Next, the CCI is associated to LOS,
length of ICU stay, and in-hospital costs, which add clinical value to
this morbidity index. Finally, the most relevant finding for the CCI is
that the required sample sizes in trials are up to 9 times lower for the
CCI than for other endpoints.
Reporting outcomes of surgical or other invasive procedures
using morbidity, as the primary endpoint, has been associated with se-
rious limitations because of various definitions and different interpre-
tation of postoperative events.1,2,4,5 Assessing the overall morbidity
by the presence of any complication causes the problem of ignoring
either the number of different complications occurring in a patient
after surgery or, more importantly, the severity of complications.
Recording only the most severe complication does not give weight to
either any complication of lesser importance or the total number of
complications, even though they affect the patient. As one of the first
attempts in outcome standardization, in 1992, a classification system
was proposed to grade the severity of complications according to the
degree of treatment needed to correct the complications.23 In 2004,
this original classification was revised to generate the “Clavien-Dindo
classification” on the basis of the same principles but eliminating cri-
teria such as the length of stay and newly grading complications
with readmission to ICU units because of organ dysfunction.3,6 The
Clavien-Dindo classification gained wide acceptance and became in-
creasingly used in a variety of studies and registries.24–28 However,
with this system, each complication is graded separately. For ease of
reporting, usually only the most severe complication was included,
which does not represent the “true” overall morbidity burden of sur-
gical procedures.5 The recently developed CCI is based on a formula
used in the economy, which incorporates multiple factors influencing
the globalization of a corporation decision. With this formula, all
complications, weighted by severity, are integrated in a linear scale.
It facilitates reporting not only of the in-hospital morbidity but also
at various postoperative follow-up, for example, the 90-day morbid-
ity or other time-span. Furthermore, the CCI is a primary outcome
measure, which is calculated separately for each patient regardless
of the population studied. Individual grade of complications or the
CCI represent endpoints, and thus a risk-adjustment is necessary for
proper interpretation in specific groups of patients. For example, a
higher median CCI in a hospital compared to others might not mean
better quality, particularly if the population of this specific center is
at higher risk for surgery with high incidence of comorbidities.
If future trials aim at focusing on the “overall morbidity” and
not on a specific complication related to the procedure under inves-
tigation, our current data strongly support the use of the CCI as a
primary endpoint. It seems that the required sample size for superior-
ity trials is impressively lower for the CCI than traditional endpoints,
particularly the “most severe complications” endpoint. Surgical trials
often require large sample sizes to detect a between-group difference,
which are only feasible in large and costly multicenter endeavor.
Switching to the CCI may result in a dramatic reduction of the re-
quired sample size, so the feasibility of a trial increases, whereas costs
decrease. In addition, the number of negative trials associated with a
type II error may be reduced. It is obvious that there is a substantial
number of false-negative results in the surgical trial literature that are
solely the result of insensitive endpoints.29
The strength of the current study is that the CCI was externally
tested and was apparently more responsive than existing outcome
endpoints. It may, therefore, serve as a standardized and easily appli-
cable primary endpoint in surgical trials and other medical specialties.
Furthermore, the CCI was performed on 3 different European patient
populations enrolled for different surgical procedures and diseases
supporting its broad use. Further strength in this report is the 1-year
CCI as a longitudinal measure of the overall morbidity over a certain
time. The 3 trials all enrolled patients by randomization to control for
confounding factors and bias.
There are also some limitations. Even though the CCI was ex-
ternally tested on a broad spectrum of patients undergoing a variety
of major abdominal surgical procedures, it might be still important
to test the CCI in other medical fields such as interventional radiol-
ogy, urology, and cardiology. A further limitation might be that the
3 trials were not powered for the CCI as primary endpoint. Never-
theless, this study already showed in rather small patient populations
significant between-group differences in the CCI whereas the differ-
ences in the frequencies of any and/or most severe complications were
similar.
CONCLUSIONS
The CCI offers a novel sensitive endpoint for clinical trials
that can be readily calculated (available at www.assessurgery.com).
The CCI may also allow in future better information of patients, stan-
dardized reporting in outcome research including readily available
assessment of morbidity at various time points, and increased com-
parability of quality of surgery across centers worldwide. Perhaps,
one of the most attractive aspects of the CCI is the possibility to
conduct conclusive trials with smaller sample sizes when focusing on
the “overall morbidity” as surgical outcome.
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DISCUSSANTS
A. Fingerhut (Paris, France):
First of all, I thank the organizing committee for the privilege
of commenting on this paper, complementing the previous, recently
published paper in Annals of Surgery from the same team on the CCI
(K. Slankamenac et al, Ann Surg. 2013;258:1–7). The senior author,
Professor Clavien, has devoted more than 20 years of his career to
postoperative complications, in terms of how to grade their severity
and evaluating their impact on postoperative outcomes. I had the
privilege of seeing and correcting the very first paper published on
the subject, in Europe, when I taught medical writing in Switzerland
several years ago.
I have several comments and questions.
One endpoint that was used in France for many years, when
the current French Association for Research “FRENCH” was called
“ARC” (Association pour la Recherche en Chirurgie), was the number
of patients, which had one complication or more. Although a possible
drawback of this endpoint might be that, admittedly, it may have
overestimated rates of severe complications, it also has to be said that
it never underestimated morbidity, which may be the case with many
of the other systems, including this one, when subjective judgment,
albeit limited here (the so-called “operation risk index” and use of
analogue scales), intervenes. My first question is as follows: is our
“ARC” endpoint (number of patients with 1 or more complications)
much different from your calculation in Table 4: “presence (or not)
of at least 1 complication”?
The difference seems to be semantic, at the worst.
Of note, the difference in the number of patients necessary for
an RCT differs very little, when this number is calculated, based on
the amount of patients with “at least one complication” and the “CCI”
(eg, 75 patients and 76 patients, respectively, for the pancreatic fistula
study as indicated in Table 4).
Our definition of complications also included postoperative
death, whatever the cause [again, because death may be due to a
complication that has occurred but is still unknown (undetected) to
the investigator]. If I understand correctly, death was excluded from
the CCI index calculation. How then does death (from a complication
whatever its Clavien-Dindo severity, certainly the worst outcome by
any means) intervene in the CCI?
Now to my third question, how does the CCI take into account
that a patient might have more than 1 complication, related to the same
cause (eg, surgical site infection, organ/space deep infection, and
pulmonary infection can all be due to a gastrointestinal or pancreatic-
enteric anastomotic leak)?
You stated that the main advantage of the CCI is that the power
calculation, based on the CCI delta, should reduce the number of
patients necessary for a clinical trial. Finally, how did you calculate
that a 10-point delta in the CCI would correspond to a clinically
relevant change in outcome? (here, in the first example. In Table 4,
grades A, B, and C pancreatic fistula or not); would the same delta be
pertinent to distinguish between patients with or without only grades
B and C? Or, once again, would fistulas lead to death?
Congratulations to the authors for yet another milestone in
the evaluation of postoperative complications; certainly, we will be
hearing more about this in the near future. I am, albeit, curious to
know how to use the power calculation in practical terms.
Response From K. Slankamenac (Zurich,
Switzerland):
Thank you, Professor Fingerhut, for these relevant comments
and questions. With regard to your first question, the definition of
any complication is, indeed, the same as that of an ARC complica-
tion, as used in France. You suggested that sample size calculation
is similar using the ARC and CCI, as the main endpoint. Although
the use of an ARC complication seems better than the other conven-
tional endpoints, CCI is still superior. For example, in the esophageal
trial, the sample with the definition for any complication requires 76
patients per group, whereas 63 patients would be sufficient, if CCI
were selected. It is not surprising that the CCI is superior, because it
captures all complications and their different severities. For example,
this traditional definition of “any complication” is only defined as yes
or no, so we don’t know the severity of these complications and the
number of all complications.
Regarding your second question of whether death is included
in the CCI scale, the answer is yes. Death was arbitrarily given 100
points, the highest value on the scale. Your third question focused
on a chain of complications, asking whether each one is included in
the CCI or only the most severe. We have applied the same princi-
ples, as reported in our 5-year experience article, published in 2009,
in this journal. When complications clearly depend on each other
(chain events), we report only the most severe one. Similarly, when
complications do not depend on each other, they should be listed.
To answer your last question, concerning the choice of 10
points as a relevant delta for the sample size calculation, we would
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like to emphasize that this 10-point difference corresponds to a 40%
relative risk reduction in the traditional endpoints. This is explained
in the full manuscript.
DISCUSSANTS
C. Bassi (Verona, Italy):
First, I would like to thank you for this excellent study, which
increased our understanding of the best way to classify complications
in our patients. The main problem I see is that I’m still perplexed about
the application of the same principles in a different kind of surgery
and a specific operation. What do you think about the patients, who are
going to be treated by local anesthesia, even though they are bleeding?
How can we consider these patients in a lower grade than patients with
general anesthesia? With this system, how can we stratify different
situations in different kinds of surgery? These are my only questions.
In the future, I think that we will have to continue to search for the
best way to apply this to general surgery. Thank you.
Response From K. Slankamenac (Zurich,
Switzerland):
Thank you, Professor Bassi, for these comments and your 2
questions. First, you are questioning the validity of some aspects
of the grading system, for example, by giving a grade 3a for a
bleeding treated with local anesthesia and a grade 3b complica-
tion for the same bleeding treated under general anesthesia. Part
of the severity grading system is based on the burden of a compli-
cation on the patient and the associated risk. In this respect, there
is no doubt that general anesthesia is more invasive than local anes-
thesia. This fact was well-reflected in a large study, which asked
patients, nurses, and physicians to estimate the severity of differ-
ent complication scenarios on a numerous analog scale. Of note,
the Clavien-Dindo grading system allows for the combination of
grade 3a and 3b complications, and thus, only reports grade 3 com-
plications, so that there is no difference in the use of general or
local anesthesia. Similarly, grade 4a (single organ failure) and 4b
(multiple organ failure) can be combined and presented as grade 4
complications.
Your second question relates to the principles of the morbidity
scale applied in different types of surgery. We believe that this is, in
fact, a strength of both the Clavien-Dindo system and CCI, which
enable conclusive comparisons to be drawn among different or same
procedures over time, or even now, with the CCI, to longitudinally
assess the postoperative course, for example, at discharge, after 3
months, 1 year, etc.
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